Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTRI/2020/04/024719
CTRI/2020/04/024719CompletedPhase 3

Comparative clinical study to evaluate the efficacy of Shigru Kwatha and Gokshura Churna in the management of Essential Hypertension- Randomized Control Study

Ayurvedic and Unani Tibbia College and Hospital0 sites60 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Enrollment
60
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • •1. Subjects willing to participate and able to provide written informed consent.
  • •2. Subjects belonging to either gender between the age group 20 to 60 years.
  • •3. Patient diagnosed as Stage- 1 E.H.T. would be selected for study on the basis of 7th JNC & WHO criteria.
  • •4. Subjects who are able to come for follow up on fixed visits and are well aware about the treatment plan.

Exclusion Criteria

  • •1. Already diagnosed cases of Cardiovascular disease/ Cerebrovascular disease / Renal disease/ Hypertensive Retinopathy.
  • •2. Subjects with any unstable Heart disease or known cases of MI, unstable angina or CHF.
  • •3. Patients with concurrent Hepatic Dysfunction (defined as AST and/or ALT > 2 times of the upper normal limit) or Renal Dysfunction, uncontrolled Pulmonary Dysfunction (asthmatic and COPD subjects).
  • •4. Subjects with current or past diagnosis of malignancy (any malignancy diagnosis in last five years).
  • •5. Subjects who have a recent history or who are currently known to abuse of alcohol or drugs.
  • •6. Subjects suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho-Neuro-Endocrinal disorders, TB, AIDS etc).
  • •7. Female subject of child bearing potential who do not agree to remain abstinent or use medically acceptable methods of contraception during the study therapy and for 4 weeks after the end of study therapy.
  • •8. Pregnant / Lactating women.
  • •9. Subject on systemic or oral steroids, oral contraceptive pills or estrogen replacement therapy.
  • •10. Subjects having hypersensitivity to any of the trial drug.
  • •11. Subjects who have completed participation in any other clinical trial during the past six (06) months.
  • •12. Pregnancy induced hypertension.

Investigators

Sponsor
Ayurvedic and Unani Tibbia College and Hospital

Similar Trials

Not yet recruiting
Phase 3
Role of ayurvedic drug orally and through nasal administration in adolescent migraine.
CTRI/2023/07/055575Dr Namrata Nandkumar Kamble
Not yet recruiting
Phase 2
Compare effect of Dhatryadi Kwath and Trunapanchmoola Kwath in urinary tract infectio
CTRI/2023/08/056532Dr Pradnya Shukracharya Kolhal
Not yet recruiting
Not Applicable
TO SEE THE EFICACY OF UPANAHA AND BASTI IN CHRONIC ANKLE SPRAIN DUE TO SPORTS INJURY AND COMPARE THE BOTH.
CTRI/2020/06/025631Register Uttarakhand Ayurved University
Not yet recruiting
Phase 2
Comparative clinical study to evaluate the efficacy of Ayurveda medicine and folklore medicine in Mootrashmari.
CTRI/2022/04/042204SDM College of Ayurveda and Hospital Hassan Karnataka
Recruiting
Not Applicable
Comparison of Punarnavadi Churna with and without Agnikarma in Gridhrasi (Sciatica)
CTRI/2020/02/023286Dr Amey Chandrakant Nakil